Scholarlink

<p>This is a summary of the original article “Apremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase&#xa0;3 trial”. Enrolled patients were aged 6–17&#xa0;years with moderate to severe plaque psoriasis (PsO) inadequately controlled by, or inappropriate for, topical therapy (NCT03701763).&#xa0;Patients were randomized to apremilast or placebo for 16&#xa0;weeks, after which all patients transitioned to apremilast through 52&#xa0;weeks. The efficacy of apremilast was assessed by disease duration at baseline (shorter, &lt; 2&#xa0;years; medium, ≥ 2 to &lt; 5&#xa0;years; longer, ≥ 5&#xa0;years). In this post hoc analysis, patients had generally similar baseline characteristics across disease durations. At week&#xa0;16, patients receiving apremilast vs placebo experienced numerically greater improvements in most skin clearance outcomes across all disease durations, particularly in patients with disease duration &lt; 2&#xa0;years. Through week&#xa0;52, patients experienced numerical improvements across all disease durations, with the most pronounced efficacy in patients with disease duration &lt; 5&#xa0;years. These findings suggest early intervention with a systemic therapy such as apremilast in pediatric patients with moderate to severe PsO may mitigate disease burden.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月14日

查看全文
  • Richard G. Langley,
  • Lisa Arkin,
  • Loretta Fiorillo,
  • Lawrence F. Eichenfield,
  • Mark Lebwohl,
  • Bruce Strober,
  • Michael Sticherling,
  • Lisa Swanson,
  • Georgios Kokolakis,
  • Siddharth Chaudhari,
  • Cynthia Deignan,
  • Zuoshun Zhang,
  • Amy S. Paller

摘要

This is a summary of the original article “Apremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial”. Enrolled patients were aged 6–17 years with moderate to severe plaque psoriasis (PsO) inadequately controlled by, or inappropriate for, topical therapy (NCT03701763). Patients were randomized to apremilast or placebo for 16 weeks, after which all patients transitioned to apremilast through 52 weeks. The efficacy of apremilast was assessed by disease duration at baseline (shorter, < 2 years; medium, ≥ 2 to < 5 years; longer, ≥ 5 years). In this post hoc analysis, patients had generally similar baseline characteristics across disease durations. At week 16, patients receiving apremilast vs placebo experienced numerically greater improvements in most skin clearance outcomes across all disease durations, particularly in patients with disease duration < 2 years. Through week 52, patients experienced numerical improvements across all disease durations, with the most pronounced efficacy in patients with disease duration < 5 years. These findings suggest early intervention with a systemic therapy such as apremilast in pediatric patients with moderate to severe PsO may mitigate disease burden.